Your browser is no longer supported. Please, upgrade your browser.
Settings
CRVS Corvus Pharmaceuticals, Inc. daily Stock Chart
CRVS [NASD]
Corvus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.57 Insider Own10.00% Shs Outstand29.49M Perf Week-17.91%
Market Cap104.10M Forward P/E- EPS next Y-1.34 Insider Trans4.75% Shs Float24.35M Perf Month20.48%
Income-46.10M PEG- EPS next Q-0.33 Inst Own78.80% Short Float5.57% Perf Quarter-1.67%
Sales- P/S- EPS this Y37.20% Inst Trans-5.36% Short Ratio9.21 Perf Half Y-2.75%
Book/sh2.74 P/B1.29 EPS next Y13.00% ROA-43.30% Target Price9.75 Perf Year-35.58%
Cash/sh2.93 P/C1.20 EPS next 5Y- ROE-48.40% 52W Range2.53 - 8.10 Perf YTD-3.81%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-56.42% Beta1.01
Dividend %- Quick Ratio9.20 Sales past 5Y- Gross Margin- 52W Low39.53% ATR0.43
Employees49 Current Ratio9.20 Sales Q/Q- Oper. Margin- RSI (14)49.96 Volatility13.43% 12.35%
OptionableYes Debt/Eq0.00 EPS Q/Q-3.70% Profit Margin- Rel Volume1.66 Prev Close3.54
ShortableYes LT Debt/Eq0.00 EarningsJan 28 AMC Payout- Avg Volume147.31K Price3.53
Recom1.50 SMA204.28% SMA506.32% SMA200-9.09% Volume245,002 Change-0.28%
Sep-12-19Initiated Mizuho Buy
May-29-19Initiated ROTH Capital Buy $6
Aug-24-17Upgrade Credit Suisse Underperform → Neutral
May-01-17Downgrade Credit Suisse Neutral → Underperform
Apr-18-16Initiated Guggenheim Buy
Apr-18-16Initiated Credit Suisse Outperform
Dec-07-19 09:00AM  Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-08-19 07:00AM  Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire -9.21%
Nov-07-19 08:30AM  Corvus Pharmaceuticals to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-05-19 08:30AM  Corvus Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference GlobeNewswire
Nov-04-19 08:30AM  Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 8, 2019 GlobeNewswire +12.43%
Nov-02-19 01:01AM  Edited Transcript of CRVS earnings conference call or presentation 29-Oct-19 8:30pm GMT Thomson Reuters StreetEvents
Oct-29-19 04:05PM  Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results GlobeNewswire
Oct-18-19 11:01AM  Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth Simply Wall St.
Oct-17-19 08:30AM  Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2019 Financial Results on October 29, 2019 GlobeNewswire +5.71%
Oct-03-19 08:30AM  Corvus Pharmaceuticals to Present Updated Data from CPI-006 Clinical Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Sep-03-19 01:28PM  How Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Can Impact Your Portfolio Volatility Simply Wall St.
Aug-10-19 11:17AM  Edited Transcript of CRVS earnings conference call or presentation 1-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-07-19 04:05PM  Corvus Pharmaceuticals to Present at the 2019 Wedbush Healthcare Conference GlobeNewswire
Aug-01-19 04:05PM  Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial Results GlobeNewswire
Jul-24-19 04:15PM  Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2019 Financial Results on August 1, 2019 GlobeNewswire -6.52%
Jul-03-19 11:14AM  Need To Know: Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insiders Have Been Buying Shares Simply Wall St. +25.50%
Jun-02-19 10:45AM  Corvus Pharmaceuticals Presents Initial CPI-006 Phase 1/1b Clinical Data at 2019 ASCO Annual Meeting GlobeNewswire
May-28-19 08:30AM  Corvus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference GlobeNewswire
May-25-19 01:28PM  Edited Transcript of CRVS earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-16-19 08:30AM  Corvus Pharmaceuticals to Present Initial Clinical Data from CPI-006 Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire -5.86%
May-09-19 05:05PM  Corvus: 1Q Earnings Snapshot Associated Press
04:02PM  Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results GlobeNewswire
May-01-19 04:10PM  Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2019 Financial Results on May 9, 2019 GlobeNewswire
Apr-26-19 03:07PM  Introducing Corvus Pharmaceuticals (NASDAQ:CRVS), The Stock That Slid 65% In The Last Three Years Simply Wall St.
Mar-07-19 04:10PM  Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-05-19 04:15PM  Corvus Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Feb-06-19 08:30AM  Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference GlobeNewswire +5.70%
Jan-30-19 08:30AM  Corvus Pharmaceuticals to Present Updated Biomarker and Clinical Data on Lead Development Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference GlobeNewswire
Jan-28-19 04:05PM  Corvus Pharmaceuticals Announces Appointment of New Member of Board of Directors and Hiring of Chief Medical Officer GlobeNewswire
Jan-22-19 12:05PM  Have Insiders Been Buying Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares This Year? Simply Wall St. -8.98%
Jan-10-19 08:30AM  Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas GlobeNewswire
Jan-08-19 08:30AM  Corvus Announces Enrollment in Second Arm of Phase 1/1b Dose-Escalation Trial of Anti-CD73 Antibody, CPI-006, Focused on Combination with CPI-444 Adenosine Antagonist GlobeNewswire
Dec-28-18 08:52AM  Ziopharm Oncology (ZIOP) in Focus: Stock Moves 6.2% Higher Zacks +9.73%
Nov-23-18 09:03AM  Sarepta Stock More Than Doubles This Year So Far: Here's Why Zacks
Nov-13-18 07:30AM  Report: Exploring Fundamental Drivers Behind Berry Petroleum, Quotient, Virco Manufacturing, Corvus Pharmaceuticals, Marine Products, and Hamilton Beach Brands Holding New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-12-18 08:30AM  Corvus Pharmaceuticals to Present at the 27th Annual Credit Suisse Healthcare Conference GlobeNewswire -5.06%
Nov-10-18 05:00PM  Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting GlobeNewswire
Nov-05-18 06:31PM  Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 10, 2018 GlobeNewswire
Nov-02-18 05:12AM  Corvus: 3Q Earnings Snapshot Associated Press
Nov-01-18 04:10PM  Corvus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire +8.04%
Oct-22-18 08:30AM  Corvus Pharmaceuticals Announces New Data on Adenosine Gene Signature Biomarker Associated with Patient Response to CPI-444 at European Society for Medical Oncology (ESMO) 2018 Congress GlobeNewswire
Oct-04-18 04:15PM  Corvus Pharmaceuticals to Present Data on Lead Programs at the European Society for Medical Oncology (ESMO) 2018 Congress and the Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Oct-03-18 04:15PM  Corvus Pharmaceuticals Announces Publication of Preclinical Results Highlighting Antitumor Activity of CPI-444 in Multiple Tumor Models both as Monotherapy and in Combination Studies GlobeNewswire +6.94%
07:46AM  Corvus Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Sep-25-18 04:15PM  Corvus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Aug-02-18 06:45PM  Corvus: 2Q Earnings Snapshot Associated Press
04:15PM  Corvus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Jul-31-18 04:15PM  Corvus Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jun-28-18 08:30AM  Corvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy and in Combination with Anti-PD-1 Therapy in Cancer Immunology, Immunotherapy GlobeNewswire
May-30-18 04:15PM  Corvus Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-03-18 07:35PM  Corvus: 1Q Earnings Snapshot Associated Press
04:10PM  Corvus Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Apr-26-18 08:30AM  Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer GlobeNewswire
Mar-19-18 07:40AM  Blog Exposure - Checkpoint Therapeutics to Present Preclinical Data on its BET Inhibitor CK-103 at AACR Meeting ACCESSWIRE
Mar-12-18 09:15AM  Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock GlobeNewswire
Mar-08-18 09:04AM  Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
Mar-07-18 04:06PM  Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire +5.31%
Mar-06-18 08:30AM  Corvus Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference 2018 GlobeNewswire +5.73%
Mar-01-18 06:33PM  Corvus reports 4Q loss Associated Press
04:10PM  Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update GlobeNewswire
Feb-01-18 08:30AM  Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma Forum GlobeNewswire
Nov-11-17 05:45PM  Corvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection GlobeNewswire
Nov-06-17 05:38AM  Corvus reports 3Q loss Associated Press
Nov-02-17 04:10PM  Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program Update GlobeNewswire
Oct-18-17 04:10PM  Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting GlobeNewswire
Sep-20-17 04:10PM  Corvus Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Aug-11-17 07:10PM  Corvus Pharmaceuticals to Present at the 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-05-17 01:10AM  Corvus reports 2Q loss Associated Press
Aug-03-17 04:10PM  Corvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Jul-06-17 04:10PM  Corvus Pharmaceuticals to Host R&D Day Highlighting Role of Adenosine Pathway in Immuno-Oncology GlobeNewswire
Jun-05-17 08:30AM  Corvus Pharmaceuticals Announces Interim Results Demonstrating Anti-Tumor Activity of CPI-444 in Renal and Lung Cancer Patients Resistant or Refractory to Prior PD-(L)1 Treatment GlobeNewswire
May-15-17 08:30AM  Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 in Renal and Lung Cancer at 2017 ASCO Annual Meeting GlobeNewswire
May-09-17 08:30AM  Corvus Pharmaceuticals and Monash University Enter into Exclusive License Agreement for Novel Immuno-Oncology Program GlobeNewswire
May-08-17 08:00AM  Q1 Losses Couldn't Drag Regulus or Corvus Pharmaceuticals Down Accesswire
May-05-17 05:02AM  Corvus reports 1Q loss Associated Press
May-04-17 04:10PM  Corvus Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
May-02-17 08:30AM  Corvus Pharmaceuticals Expands CPI-444 Clinical Collaboration with Genentech GlobeNewswire
Apr-06-17 11:59AM  Top Ranked Momentum Stocks to Buy for April 6th Zacks
07:30AM  Today's Research Reports on Biotech Stocks to Watch: Corvus Pharmaceuticals and Neothetics Accesswire
Apr-05-17 04:58PM  Disappointment In Corvus Pharma Understandable, But Selloff May Have Been Overdone Benzinga
12:40PM  Corvus Reports Positive Cancer Study Data Investopedia
Apr-04-17 04:48PM  Why NVIDIA, Corvus Pharmaceuticals, and J.C. Penney Slumped Today Motley Fool
10:30AM  Corvus Pharmaceuticals Announces Interim Results from Ongoing Phase 1/1b Study Demonstrating Safety and Clinical Activity of Lead Checkpoint Inhibitor CPI-444 in Patients with Advanced Cancers GlobeNewswire
08:58AM  3 Reasons Why Corvus Pharmaceuticals (CRVS) is a Great Momentum Stock Zacks
Apr-03-17 09:50AM  AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval
Mar-27-17 10:08AM  AstraZeneca's Lung Cancer Drug Tagrisso Approved in China
Mar-24-17 05:34AM  Can the Rally in Corvus Pharmaceuticals (CRVS) Shares Continue? Zacks
Mar-20-17 08:30AM  Corvus Pharmaceuticals to Present Data That Advances the Understanding of the Adenosine Pathway in Immuno-Oncology, including New Clinical Data on CPI-444 at AACR 2017 GlobeNewswire
Mar-16-17 01:04PM  CORVUS PHARMACEUTICALS, INC. Financials
Mar-13-17 04:25PM  Lilly, Merck, Allergan Top Analyst's View For 2017 Pharma
08:00AM  Corvus Pharmaceuticals to Reschedule R&D Day Due to Severe Winter Storm in the New York Tri-State Area GlobeNewswire
Mar-10-17 08:14AM  Corvus reports 4Q loss Associated Press
08:01AM  CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
08:00AM  Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update GlobeNewswire
Mar-09-17 08:30AM  Corvus Pharmaceuticals to Host R&D Day Highlighting the Role of the Adenosine Pathway in Immuno-Oncology GlobeNewswire
Feb-27-17 08:30AM  Corvus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference 2017 GlobeNewswire
Feb-14-17 09:02AM  CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
Jan-10-17 08:31AM  CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
08:30AM  Corvus Pharmaceuticals Announces Expansion of Renal Cell Carcinoma Cohort in Ongoing Phase 1/1b Clinical Study of Lead Checkpoint Inhibitor CPI-444 GlobeNewswire
Jan-04-17 04:10PM  Corvus Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference 2017 GlobeNewswire
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILLER RICHARD A MDPresident and CEONov 13Buy3.0014,73644,2401,178,515Nov 14 04:14 PM
MILLER RICHARD A MDPresident and CEONov 12Buy2.902727891,163,779Nov 14 04:14 PM
MILLER RICHARD A MDPresident and CEOAug 07Buy3.542,5008,8501,163,507Aug 08 04:07 PM
Thompson Peter A.DirectorAug 06Buy3.51142,656500,7236,767,584Aug 08 05:00 PM
ORBIMED ADVISORS LLCDirectorAug 06Buy3.51142,656500,7236,767,584Aug 08 04:59 PM
MILLER RICHARD A MDPresident and CEOAug 06Buy3.585,00017,8751,161,007Aug 08 04:07 PM
Novo Holdings A/S10% OwnerJul 25Sale4.001,400,0005,600,0002,927,560Jul 25 07:21 PM
Novo Holdings A/S10% OwnerJul 24Sale5.0153,240266,7114,327,560Jul 25 07:21 PM
Novo Holdings A/S10% OwnerJul 23Sale5.3239,716211,1344,380,800Jul 25 07:21 PM
Thompson Peter A.DirectorJul 01Buy3.9159,243231,6406,624,928Jul 01 06:16 PM
ORBIMED ADVISORS LLCDirectorJul 01Buy3.9159,243231,6406,624,928Jul 01 06:15 PM
Thompson Peter A.DirectorJun 28Buy3.72565,1782,102,4626,565,685Jul 01 06:16 PM
ORBIMED ADVISORS LLCDirectorJun 28Buy3.72565,1782,102,4626,565,685Jul 01 06:15 PM
Thompson Peter A.DirectorJun 27Buy3.3432,923109,9636,000,507Jul 01 06:16 PM
ORBIMED ADVISORS LLCDirectorJun 27Buy3.3432,923109,9636,000,507Jul 01 06:15 PM
MILLER RICHARD A MDPresident and CEOJun 14Buy3.4011,65739,6661,156,007Jun 17 04:08 PM
MILLER RICHARD A MDPresident and CEOJun 13Buy3.523431,2071,144,350Jun 17 04:08 PM
MILLER RICHARD A MDPresident and CEOJun 11Buy3.676,00022,0201,144,007Jun 11 04:55 PM
MILLER RICHARD A MDPresident and CEOJun 07Buy3.379,21231,0191,138,007Jun 11 04:55 PM
LEA LEIVChief Financial OfficerJun 07Buy3.3810,00033,80050,200Jun 10 04:12 PM
LEA LEIVChief Financial OfficerJun 06Buy3.5615,50055,18040,200Jun 10 04:12 PM
MILLER RICHARD A MDPresident and CEODec 27Buy3.2920,00065,8841,128,795Dec 31 04:16 PM
LEA LEIVChief Financial OfficerDec 21Buy4.1524,700102,40924,700Dec 27 04:08 PM
MILLER RICHARD A MDPresident and CEODec 20Buy4.4010,00043,9501,108,795Dec 26 04:05 PM